Literature DB >> 7740657

Drug therapy of bacillus Calmette-Guérin sepsis.

S C Koukol1, J I DeHaven, D R Riggs, D L Lamm.   

Abstract

Intravesical bacillus Calmette-Guérin (BCG) is widely used for the treatment of transitional cell carcinoma of the bladder. Although it is usually well tolerated, sepsis can occur, which has resulted in at least eight deaths [3]. The survival of Connaught BCG-infected mice treated with single and combination antibiotic and steroid therapy was evaluated. Triple-drug therapy with isoniazid, rifampin, and prednisolone resulted in 53% survival compared with 25% survival in the control group (P = 0.0209). A survival of only 10.5% was observed with treatment using prednisolone alone. This survival was worse than that of the control group (25%), and approached statistical significance (P = 0.0669). Our data suggest that BCG sepsis probably has components of both a hypersensitivity reaction and bacterial sepsis; they support the current use of combination antibiotic and steroid therapy for treatment of BCG sepsis in humans, but argue against treatment with steroids alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740657     DOI: 10.1007/BF00296878

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  6 in total

1.  Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

Authors:  W H Rawls; D L Lamm; B A Lowe; E D Crawford; M F Sarosdy; J E Montie; H B Grossman; P T Scardino
Journal:  J Urol       Date:  1990-12       Impact factor: 7.450

2.  Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.

Authors:  R J Torrence; L R Kavoussi; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

3.  Granulomatous hepatitis: a complication of B.C.G. immunotherapy.

Authors:  J S Hunt; M J Silverstein; F C Sparks; C M Haskell; Y H Pilch; D L Morton
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

4.  Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.

Authors:  C F McKhann; C G Hendrickson; L E Spitler; A Gunnarsson; D Banerjee; W R Nelson
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

5.  Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity.

Authors:  J I DeHaven; C Traynellis; D R Riggs; E Ting; D L Lamm
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

  6 in total
  1 in total

1.  Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates.

Authors:  Kristopher Kolibab; Steven C Derrick; Sheldon L Morris
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.